Titel | Safety of intra-vitreal injections : a 3-year experience |
Doel | to evaluate the safety of intra-vitreal injections . |
Methodes | retrospective study of patients treated by a standart protocole of intra-vitreal injection. Evaluation of per and post-operative complications. |
Resultaten | 1523 eyes received an intra-vitreal injection over a period of 32 months. Bevacizumab was injected in 843 eyes, ranibizumab in 402 eyes, pegaptanib in 223 eyes and triamcinolone acetonide in 55 eyes. Bulbar ecchymosis was frequent, allergic reaction to topical drops or povidone iodine was reported, reversible central artery occlusion occurred in 3 eyes (0.2 %), pseudo-uveitis in 1 eye (0.065 %), uveitis in 2 eyes (0.13 %) and endophthalmitis in 1 eye (0.065 %). No cases of vitreal hemorraghe, posterior capsule rupture, lens injury, retinal detachment or retinal tear were described. |
Conclusie | In our practice, complications of intra-vitreal injections are rare and often reversible. Endophthalmitis is exceptional and occurred in only 1 eye (0.065 %). Intra-vitreal injections are a safe procedure when standart protocole is used. |
Naam | GUAGNINI |
Initialen | AP |
Instituut | Cliniques Universitaires Saint-Luc, UCL |
Stad | Bruxelles |
Naam | Snyers |
Initialen | B |
Instituut | Cliniques Universitaires Saint-Luc, UCL |
Stad | Bruxelles |
Naam | Kozyreff |
Initialen | A |
Instituut | Cliniques Universitaires Saint-Luc, UCL |
Stad | Bruxelles |